anti-PSMA CAR T-cell therapy (Nova Therapeutics)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-PSMA CAR T-cell therapy (Nova Therapeutics)
Drug Alias NameCART-PSMA Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNova Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesNova Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A